フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing...
Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP...
The Gross Law Firm Notifies Metagenomi, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline...
November 25, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MGX PR Newswire NEW...
Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action...
Class Action Filed Against Metagenomi, Inc. (MGX) Seeking Recovery for Investors - Contact The Gross Law...
Initiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable...
Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class...
EMERYVILLE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic...
Metagenomi, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 25, 2024 to...
Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before...
Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class Action - Contact The Gross Law Firm...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約